Ono Pharmaceutical (United Kingdom)

Recent papers from Ono Pharmaceutical (United Kingdom)

1. Disease Progression in Multiple System Atrophy: The ASPIRE Multi‐Modal Biomarker StudyAnnals of Neurology · 2025
2. Early administration of anamorelin improves cancer cachexia in patients with gastrointestinal cancer: An observational study2024
3. Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma2024
4. Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung CancerJTO Clinical and Research Reports · 2024
5. Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA StudyJTO Clinical and Research Reports · 2023
6. ONO‐7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human studyBritish Journal of Clinical Pharmacology · 2021
7. Prospective cohort study of surgical outcome for spinal metastases in patients aged 70 years or olderThe Bone & Joint Journal · 2020
8. Efficacy and Safety of Landiolol in Patients With Ventricular Tachyarrhythmias With or Without Renal Impairment ― Subanalysis of the J-Land II Study ―Circulation Reports · 2020
9. Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based RegistryJournal of Global Oncology · 2019
10. Fp031etelcalcetide (Parsabiv®, Amg 416/Ono-5163) Directly Reduced Parathyroid Hormone Levels in Human Parathyroid Cell CultureNephrology Dialysis Transplantation · 2019
11. SAT-430 A Phase 1 Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of ONO-5788: A Novel Oral Small Molecule Somatostatin Receptor Type-2 AgonistJournal of the Endocrine Society · 2019
12. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid TumorsJournal of Clinical Oncology · 2018
13. Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With ChemoradiotherapyJournal of Cancer · 2018
14. Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosisBMC Musculoskeletal Disorders · 2017
15. Brain translocator protein occupancy by ONO‐2952 in healthy adults: A Phase 1 PET study using [11C]PBR28Synapse · 2017
16. Randomised clinical trial: exploratory phase 2 study of ONO ‐2952 in diarrhoea‐predominant irritable bowel syndromeAlimentary Pharmacology & Therapeutics · 2016
17. Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised studyBritish Journal of Ophthalmology · 2016
18. Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation StudyPublisher · 2016
19. First Clinical Experience with ONO-4232: A Randomized, Double-blind, Placebo-controlled Healthy Volunteer Study of a Novel Lusitropic Agent for Acutely Decompensated Heart FailureClinical Therapeutics · 2016
20. Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure　– A Randomized, Double-Blind, Placebo-Controlled Phase II Study –Circulation Journal · 2016